Usui T, et al. - Researchers evaluated the persistence rates and switches before and after teriparatide treatment in real-world osteoporosis patients based on data from a medical claims database in Japan. The spine was the most common fracture site. Results demonstrated 34.9% to be persistence rate over 12 months of teriparatide treatment in Japan. As per data, 38.2% were switched to active vitamin D3 following teriparatide, 35.1% to bisphosphonates, and 13.7% to denosumab allowing duplication. No subsequent treatment was seen in approximately one-third of patients immediately after teriparatide. For teriparatide treatment, monitoring persistence and considering subsequent drugs for osteoporosis were necessary.